MX2024008172A - Procedimiento para la preparación del ácido (5s)-{[2-(4-carboxifenil)etil][2- (2-{[3-cloro-4'-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]amino}-5,6,7,8- tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo - Google Patents

Procedimiento para la preparación del ácido (5s)-{[2-(4-carboxifenil)etil][2- (2-{[3-cloro-4'-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]amino}-5,6,7,8- tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo

Info

Publication number
MX2024008172A
MX2024008172A MX2024008172A MX2024008172A MX2024008172A MX 2024008172 A MX2024008172 A MX 2024008172A MX 2024008172 A MX2024008172 A MX 2024008172A MX 2024008172 A MX2024008172 A MX 2024008172A MX 2024008172 A MX2024008172 A MX 2024008172A
Authority
MX
Mexico
Prior art keywords
ethyl
tetrahydroquinoline
carboxyphenyl
biphenyl
trifluoromethyl
Prior art date
Application number
MX2024008172A
Other languages
English (en)
Spanish (es)
Inventor
Britta Olenik
Birgit Keil
Bernd Rösler
Peter Fey
Heiko Schirmer
Guido Becker
Julian Egger
Clemens Bothe
Helene Faber
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of MX2024008172A publication Critical patent/MX2024008172A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2024008172A 2021-12-29 2024-06-27 Procedimiento para la preparación del ácido (5s)-{[2-(4-carboxifenil)etil][2- (2-{[3-cloro-4'-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]amino}-5,6,7,8- tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo MX2024008172A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21218163 2021-12-29
PCT/EP2022/087952 WO2023126436A1 (en) 2021-12-29 2022-12-28 Process for preparing (5s)-{[2-(4-carboxyphenyl)ethyl] |2-(2-{|3-chloro-4'-(trifluoromethyl)biphenyl-4- yl]methoxy}phenyl)ethyl]aminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and its crystalline forms for use as pharmaceutically active compound

Publications (1)

Publication Number Publication Date
MX2024008172A true MX2024008172A (es) 2025-04-02

Family

ID=79185525

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024008172A MX2024008172A (es) 2021-12-29 2024-06-27 Procedimiento para la preparación del ácido (5s)-{[2-(4-carboxifenil)etil][2- (2-{[3-cloro-4'-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]amino}-5,6,7,8- tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo

Country Status (12)

Country Link
US (2) US12202805B2 (https=)
EP (1) EP4457215A1 (https=)
JP (1) JP2025502842A (https=)
KR (1) KR20240144177A (https=)
CN (1) CN118765272A (https=)
AR (1) AR128147A1 (https=)
AU (1) AU2022429647A1 (https=)
CA (1) CA3244893A1 (https=)
IL (1) IL313922A (https=)
MX (1) MX2024008172A (https=)
TW (1) TW202342012A (https=)
WO (1) WO2023126436A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240144177A (ko) 2021-12-29 2024-10-02 바이엘 악티엔게젤샤프트 (5s)-{[2-(4-카르복시페닐)에틸][2-(2-{[3-클로로-4'-(트리플루오로메틸)비페닐-4-일]메톡시}페닐)에틸]아미노}-5,6,7,8-테트라히드로퀴놀린-2-카르복실산및 약학적 활성 화합물로서 사용하기 위한 이의 결정질 형태를 제조하는 방법
EP4456896A1 (en) 2021-12-29 2024-11-06 Bayer Aktiengesellschaft Treatment of cardiopulmonary disorders

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8004002L (sv) 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
IL65501A (en) 1981-05-08 1986-04-29 Astra Laekemedel Ab 1-alkyl-2-aminotetralin derivatives,process for their preparation and pharmaceutical compositions containing them
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
DE3719924A1 (de) 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
KR100195656B1 (ko) 1989-05-31 1999-06-15 로버트 에이.아미테이지 치료학적으로 유용한 2-아미노테트랄린 유도체
FR2659853A1 (fr) 1990-03-22 1991-09-27 Midy Spa Utilisation de derives 2-aminotetraliniques pour la preparation de medicaments destines a combattre les troubles de la motricite intestinale.
DE69535315T2 (de) 1994-01-10 2007-06-28 Teva Pharmaceutical Industries Ltd. 1-aminoindanderivate und zusammensetzungen hiervon
DK1083889T3 (da) 1998-06-01 2004-04-13 Ortho Mcneil Pharm Inc Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9827467D0 (en) 1998-12-15 1999-02-10 Zeneca Ltd Chemical compounds
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10109859A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige Aminodicarbonsäurederivate
DE10109858A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige halogensubstituierte Aminodicarbonsäurederivate
DE10109861A1 (de) 2001-03-01 2002-09-05 Bayer Ag Neuartige seitenkettenhalogenierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
JP2006522634A (ja) 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
US20050032873A1 (en) 2003-07-30 2005-02-10 Wyeth 3-Amino chroman and 2-amino tetralin derivatives
JP2008534593A (ja) 2005-03-30 2008-08-28 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、そのような化合物を含む組成物、及びその使用方法
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
US20090048295A1 (en) 2007-08-13 2009-02-19 Joseph Kent Barbay Substituted 5,6,7,8-tetrahydroquinoline derivatives, compositions, and methods of use thereof
BRPI0816382A2 (pt) 2007-09-06 2015-02-24 Merck Sharp & Dohme Composto, composição, e, métodos para ativar a guanilato ciclase solúvel e para tratar ou previnir doenças
JP2011185957A (ja) 2008-07-04 2011-09-22 Sharp Corp 偏光板、表示装置及びその製造方法
JP5937353B2 (ja) 2008-08-19 2016-06-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 冷感−メントール受容体拮抗剤
DE102010020553A1 (de) 2010-05-14 2011-11-17 Bayer Schering Pharma Aktiengesellschaft Substituierte 8-Alkoxy-2-aminotetralin-Derivate und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2687210A1 (de) 2010-06-25 2014-01-22 Bayer Intellectual Property GmbH Verwendung von Stimulatoren und Aktivatoren der löslichen Guanylatzyklase zur Behandlung von Sichelzellanämie und Konservierung von Blutersatzstoffen
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
JP5715713B2 (ja) 2011-03-10 2015-05-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性グアニル酸シクラーゼ活性化因子
AU2012295802B2 (en) 2011-08-12 2017-03-30 Nissan Chemical Industries, Ltd. Tricyclic heterocyclic compounds and JAK inhibitors
KR20140144696A (ko) 2012-04-16 2014-12-19 도아 에이요 가부시키가이샤 ２환성 화합물
CA2879456A1 (en) 2012-07-20 2014-01-23 Bayer Pharma Aktiengesellschaft Substituted aminoindane- and aminotetralincarboxylic acids and use thereof
RS55651B1 (sr) 2012-07-20 2017-06-30 Bayer Pharma AG Nove 5-aminotetrahidrohinolin-2-karbonske kiseline i njihova upotreba
US9624214B2 (en) 2012-11-05 2017-04-18 Bayer Pharma Aktiengesellschaft Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft USE OF SGC ACTIVATORS AND STIMULATORS COMPRISING A BETA2 SUBUNIT
IL298316A (en) 2020-05-20 2023-01-01 Bayer Ag Process for preparing butyl-(5s)-5-({2-[4-(butoxycarbonyl)phenyl]ethyl}[2-(2-{[3-chloro-4'-(trifluoromethyl)[biphenyl]-4-yl) methoxy}phenyl)ethyl]amino)-8,7,6,5-tetrahydroquinoline-2-carboxylate
KR20240144177A (ko) 2021-12-29 2024-10-02 바이엘 악티엔게젤샤프트 (5s)-{[2-(4-카르복시페닐)에틸][2-(2-{[3-클로로-4'-(트리플루오로메틸)비페닐-4-일]메톡시}페닐)에틸]아미노}-5,6,7,8-테트라히드로퀴놀린-2-카르복실산및 약학적 활성 화합물로서 사용하기 위한 이의 결정질 형태를 제조하는 방법
AU2022427770A1 (en) 2021-12-29 2024-07-04 Bayer Aktiengesellschaft Pharmaceutical dry powder inhalation formulation
EP4456896A1 (en) 2021-12-29 2024-11-06 Bayer Aktiengesellschaft Treatment of cardiopulmonary disorders

Also Published As

Publication number Publication date
JP2025502842A (ja) 2025-01-28
KR20240144177A (ko) 2024-10-02
AU2022429647A1 (en) 2024-07-04
WO2023126436A1 (en) 2023-07-06
CN118765272A (zh) 2024-10-11
TW202342012A (zh) 2023-11-01
IL313922A (en) 2024-08-01
CA3244893A1 (en) 2023-07-06
US20250263381A1 (en) 2025-08-21
EP4457215A1 (en) 2024-11-06
US20240116874A1 (en) 2024-04-11
US12202805B2 (en) 2025-01-21
AR128147A1 (es) 2024-03-27

Similar Documents

Publication Publication Date Title
MX2024008172A (es) Procedimiento para la preparación del ácido (5s)-{[2-(4-carboxifenil)etil][2- (2-{[3-cloro-4'-(trifluorometil)bifenil-4-il]metoxi}fenil)etil]amino}-5,6,7,8- tetrahidroquinolina-2-carboxílico y sus formas cristalinas para su uso como compuesto farmacéuticamente activo
JP6251259B2 (ja) 新規の５−アミノテトラヒドロキノリン−２−カルボン酸およびその使用
ES2232114T3 (es) Derivados de cicloalqueno, procedimiento para su produccion, y uso.
KR100984939B1 (ko) 발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
JPH08510479A (ja) 眼の炎症障害を処置するための３‐ベンゾイルフェニル酢酸誘導体を含む局所的に投与可能な組成物
MXPA03010435A (es) Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
NO148583B (no) Kohesive, bare til seg selv og ikke til fremmedlegemer klebende bind for fremstilling av fikseringsbandasjer, og fremgangsmaate til fremstilling av slike bind
MX2023002547A (es) Compuestos novedosos como inhibidor de histona desacetilasa 6 y composicion farmaceutica que comprende los mismos.
PH12023550101A1 (en) Novel compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same
MX2008010884A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1.
MX2024008170A (es) Tratamiento de trastornos cardiopulmonares
MX2024014315A (es) Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas
MX2025001865A (es) Compuestos de piridinona sustituida como inhibidores de cbl-b
JOP20200133A1 (ar) طريقة لتحضير حمض (3s)-3-(4-كلورو-3-{[(2s،3r) -2-(4-كلورو فنيل) -4، 4، 4-ثلاثي فلورو-3-مثيل بيوتانويل] أمينو} فنيل) -3- بروبيل حلقي بروبانويك والشكل البلوري منه لاستخدامه كمركب فعال صيدلانياً
JP7708760B2 (ja) 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用
NO20051011L (no) Kirale oksazol-arylpropionsyrederivater og anvendelse derav som PPAR agonister
JP2025502842A5 (https=)
AU2018250965A1 (en) Heterocyclic inhibitors of lysine biosynthesis via the diaminopimelate pathway
WO2002045750A1 (en) Combination drugs
CN108503604B (zh) (4-烷基-5-酰基-2-噻唑)腙衍生物及其医药用途
MX2025003934A (es) Métodos para preparar derivados de carbamato
AU2007230948B2 (en) Modified macrophage migration inhibitory factor inhibitors
CA2456426A1 (en) New mandelic acid derivatives and their use as thrombin inhibitors
WO2024215870A3 (en) Heterocyclic compounds as inhibitors of polymerase theta and methods of use thereof
ZA202309953B (en) Novel heterocyclic compounds and their use